A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus

NCT05407961 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

90

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: LY3532226
DRUG: Placebo
DRUG: Dulaglutide

Sponsor

Eli Lilly and Company